A prospective explorative cross sectional clinical study to investigate the neurocognitive effects of human Immunodeficiency virus and the influence of highly active anti retroviral (HAART) therapy on CSF viral replication and biomarkers for neurodegeneration in HIV infected patients on chronic therapy with HAART

A prospective explorative cross sectional clinical study to investigate the neurocognitive effects of human Immunodeficiency virus and the influence of highly active anti retroviral (HAART) therapy on CSF viral replication and biomarkers for neurodegeneration in HIV infected patients on chronic therapy with HAART - Neurona-light

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33642

Enrollment

Registered

2009-04-01

Start date

2009-04-02

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuro-HIV

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • HIV-seropositive 18-65 years • On HAART therapy

Exclusion criteria

Exclusion criteria: • Active opportunistic infection • Active psychiatric disorder for which treatment is indicated • Malignancy • Neurosyphilis • Drug addiction • Excessive (> 2 U/d) use of alcohol

Design outcomes

Primary

Measure	Time frame
HIVRNA in CSF Drug levels, proteins and biomarkers for neurodegeneration in CSF	—

Secondary

Measure	Time frame
neuropsychological abnormalities abnormalities in MRI of the brain	—

Countries

Netherlands

Outcome results